- Home
- NLOP vs FHTX Comparison
NLOP vs FHTX Comparison
Compare NLOP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NLOP | FHTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 173.4M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NLOP | FHTX |
|---|---|---|
| Price | $9.57 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 148.2K | ★ 1.1M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $118,915,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | $7.60 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.51 | $1.79 |
| 52 Week High | $30.26 | $7.61 |
Technical Indicators
Market Signals| Indicator | NLOP | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 15.48 |
| Support Level | $9.51 | $1.79 |
| Resistance Level | $11.65 | $5.35 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 11.63 | 5.10 |
Price Performance
Historical ComparisonAbout NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.